These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24488444)

  • 21. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
    Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
    Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
    Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
    Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
    Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
    J Neurooncol; 2021 Sep; 154(2):207-217. PubMed ID: 34331673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
    J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy.
    Moulignier A; Lamirel C; Picard H; Lebrette MG; Amiel C; Hamidi M; Polivka M; Mikol J; Cochereau I; Pialoux G
    Neurology; 2017 Aug; 89(8):796-804. PubMed ID: 28747447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study.
    Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Tantiworawit A; Norasetthada L
    Int J Clin Oncol; 2021 Oct; 26(10):1805-1811. PubMed ID: 34236556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
    Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
    J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances and challenges in the treatment of primary central nervous system lymphoma.
    Yang H; Xun Y; Yang A; Liu F; You H
    J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
    Bokstein F; Lossos A; Lossos IS; Siegal T
    Leuk Lymphoma; 2002 Mar; 43(3):587-93. PubMed ID: 12002763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.
    Hottinger AF; DeAngelis LM; Yahalom J; Abrey LE
    Neurology; 2007 Sep; 69(11):1178-82. PubMed ID: 17846417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive functions in primary CNS lymphoma after single or combined modality regimens.
    Correa DD; Shi W; Abrey LE; Deangelis LM; Omuro AM; Deutsch MB; Thaler HT
    Neuro Oncol; 2012 Jan; 14(1):101-8. PubMed ID: 22013168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
    Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
    Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy.
    Chiesa S; Hohaus S; Falcinelli L; D'Alò F; Martelli MF; Manfrida S; Beghella Bartoli F; Colosimo C; Valentini V; Aristei C; Balducci M
    Ann Hematol; 2020 Oct; 99(10):2367-2375. PubMed ID: 32816079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma.
    Chamberlain MC; Johnston SK
    Neuro Oncol; 2010 Jul; 12(7):736-44. PubMed ID: 20511181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment for primary CNS lymphoma: the next step.
    Abrey LE; Yahalom J; DeAngelis LM
    J Clin Oncol; 2000 Sep; 18(17):3144-50. PubMed ID: 10963643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).
    Miyakita Y; Ohno M; Takahashi M; Muragaki Y; Katai H; Narita Y
    Jpn J Clin Oncol; 2017 Oct; 47(10):919-924. PubMed ID: 28981729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges and opportunities in primary CNS lymphoma: A systematic review.
    Kerbauy MN; Moraes FY; Lok BH; Ma J; Kerbauy LN; Spratt DE; Santos FP; Perini GF; Berlin A; Chung C; Hamerschlak N; Yahalom J
    Radiother Oncol; 2017 Mar; 122(3):352-361. PubMed ID: 28104300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term survival in AIDS-related primary central nervous system lymphoma.
    Gupta NK; Nolan A; Omuro A; Reid EG; Wang CC; Mannis G; Jaglal M; Chavez JC; Rubinstein PG; Griffin A; Abrams DI; Hwang J; Kaplan LD; Luce JA; Volberding P; Treseler PA; Rubenstein JL
    Neuro Oncol; 2017 Jan; 19(1):99-108. PubMed ID: 27576871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.
    Hayano A; Takashima Y; Yamanaka R
    Int J Clin Oncol; 2019 Sep; 24(9):1020-1029. PubMed ID: 30993483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.